Beyondspring (BYSI) Stock Rating Upgraded by Zacks Investment Research

Beyondspring (NASDAQ:BYSI) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Tuesday.

According to Zacks, “BeyondSpring Inc. is a clinical stage biopharmaceutical company. It focused on the development of cancer therapies. The Company’s lead product consists of into a Phase 3 clinical trial as a direct anticancer agent in non-small cell lung cancer and a Phase 2/3 clinical trial in the prevention of chemotherapy-induced Neutropenia. BeyondSpring Inc. is based in New York, United States. “

Other research analysts have also issued research reports about the company. HC Wainwright set a $60.00 price target on Beyondspring and gave the stock a “buy” rating in a research report on Friday, December 15th. Maxim Group set a $52.00 price target on Beyondspring and gave the stock a “buy” rating in a research report on Thursday, December 14th. Finally, Seaport Global Securities initiated coverage on Beyondspring in a research report on Tuesday, December 5th. They issued a “buy” rating and a $56.00 price target for the company. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $54.50.

Beyondspring (NASDAQ:BYSI) traded up $0.21 on Tuesday, reaching $27.80. The company had a trading volume of 1,200 shares, compared to its average volume of 3,550. Beyondspring has a 12 month low of $16.55 and a 12 month high of $48.49.

Beyondspring (NASDAQ:BYSI) last released its quarterly earnings results on Thursday, November 9th. The company reported ($0.68) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.69) by $0.01. analysts expect that Beyondspring will post -4.41 EPS for the current year.

A hedge fund recently bought a new stake in Beyondspring stock. Tanaka Capital Management Inc. bought a new stake in shares of Beyondspring Inc (NASDAQ:BYSI) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 21,322 shares of the company’s stock, valued at approximately $914,000. Beyondspring accounts for 2.1% of Tanaka Capital Management Inc.’s holdings, making the stock its 16th largest holding. Tanaka Capital Management Inc. owned about 0.10% of Beyondspring at the end of the most recent reporting period. Institutional investors own 1.22% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Beyondspring (BYSI) Stock Rating Upgraded by Zacks Investment Research” was reported by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this article on another domain, it was illegally copied and republished in violation of international copyright legislation. The correct version of this article can be accessed at

About Beyondspring

BeyondSpring Inc is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC).

Receive News & Ratings for Beyondspring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beyondspring and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply